Nuvation Bio Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Insider Trading Arrangements and Policies
During the Company’s last fiscal quarter, the Company’s directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated the contracts, instructions or written plans for the purchase or sale of the Company’s securities set forth below.
On December 4, 2025, David Hanley, the Company’s Chief Technical Operations Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 800,000 shares of the Company's Common Stock. Pursuant to this plan, Mr. Hanley may sell shares beginning April 4, 2026 and ending April 10, 2027.
On December 4, 2025, Gary Hattersley, the Company’s Chief Scientific Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 400,000 shares of the Company's Common Stock. Pursuant to this plan, Mr. Hattersley may sell shares beginning April 4, 2026 and ending April 1, 2027.
On December 4, 2025, David Liu, the Company’s Chief Medical Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 450,000 shares of the Company's Common Stock. Pursuant to this plan, Mr. Liu may sell shares beginning April 4, 2026 and ending April 10, 2027.
On December 4, 2025, Moses Makunje, the Company’s Chief Accounting Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 100,000 shares of the Company's Common Stock. Pursuant to this plan, Mr. Makunje may sell shares beginning April 4, 2026 and ending April 6, 2027.
On December 4, 2025, Stacy Markel, the Company’s Chief People Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 500,000 shares of the Company's Common Stock. Pursuant to this plan, Ms. Markel may sell shares beginning April 4, 2026 and ending April 6, 2027.
On December 4, 2025, Philippe Sauvage, the Company’s Chief Financial Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 590,918 shares of the Company's Common Stock. Pursuant to this plan, Mr. Sauvage may sell shares beginning April 4, 2026 and ending April 15, 2027.
On December 4, 2025, Kerry Wentworth, the Company’s Chief Regulatory Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)under the Exchange Act, providing for the saleof up to 475,090 shares of the Company's Common Stock. Pursuant to this plan, Ms. Wentworth may sell shares beginning April 4, 2026 and ending April 1, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.